These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 12380908

  • 1. Lipoprotein abnormalities in hemodialysis and continuous ambulatory peritoneal dialysis patients.
    Fytili CI, Progia EG, Panagoutsos SA, Thodis ED, Passadakis PS, Sombolos KI, Vargemezis VA.
    Ren Fail; 2002 Sep; 24(5):623-30. PubMed ID: 12380908
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Is arterial hypertension an underlying factor in the increased serum Lp(a) levels in ESRD dialyzed patients?
    Fytili CI, Passadakis PS, Progia EG, Kambouromiti GL, Panopoulou MI, Sombolos KI, Vargemezis VA.
    Ren Fail; 2002 Sep; 24(5):631-8. PubMed ID: 12380909
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
    Kanbay M, Delibasi T, Kaya A, Aydogan T, Koca C, Akcay A, Duranay M, Yigitoglu R.
    Ren Fail; 2006 Sep; 28(7):567-71. PubMed ID: 17050239
    [Abstract] [Full Text] [Related]

  • 7. Concentration of Lp(a) and other apolipoproteins in predialysis, hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients.
    Kimak E, Solski J, Janicka L, Ksaziek A, Janicki K.
    Clin Chem Lab Med; 2000 May; 38(5):421-5. PubMed ID: 10952225
    [Abstract] [Full Text] [Related]

  • 8. Increased lipoprotein (a) and its relationships with other parameters of lipoprotein metabolism in chronic renal failure treated by hemodialysis.
    Yiğitoğlu MR, Polat MF, Akçay F, Ari Z, Uyanik BS, Ozilgili HM.
    Jpn Heart J; 1997 Jan; 38(1):83-9. PubMed ID: 9186284
    [Abstract] [Full Text] [Related]

  • 9. Residual renal function affects lipid profile in patients undergoing continuous ambulatory peritoneal dialysis.
    Kagan A, Elimalech E, Lemer Z, Fink A, Bar-Khayim Y.
    Perit Dial Int; 1997 Jan; 17(3):243-9. PubMed ID: 9237284
    [Abstract] [Full Text] [Related]

  • 10. Longitudinal survey of apolipoproteins and atherogenic risk in hemodialysis and continuous ambulatory peritoneal dialysis patients.
    Burrell D, Antignani A, Fein PA, Goldwasser P, Mittman N, Avram MM.
    ASAIO Trans; 1990 Jan; 36(3):M331-5. PubMed ID: 2123635
    [Abstract] [Full Text] [Related]

  • 11. Lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease.
    Kim SB, Yang WS, Kang ES, Min WK, Park JS.
    Perit Dial Int; 1997 Jan; 17(3):236-42. PubMed ID: 9237283
    [Abstract] [Full Text] [Related]

  • 12. [Lipoprotein (a) in children with end stage renal failure on maintenance hemodialysis and continuous ambulatory peritoneal dialysis].
    Zwolińska D, Szprynger K.
    Przegl Lek; 1997 Jan; 54(5):320-3. PubMed ID: 9380806
    [Abstract] [Full Text] [Related]

  • 13. The effect of change of renal replacement therapy on serum lipoprotein (a) concentration.
    Misra M, Webb AT, Reaveley DA, Doherty E, O'Donnell M, Seed M, Brown EA.
    Adv Perit Dial; 1997 Jan; 13():168-73. PubMed ID: 9360675
    [Abstract] [Full Text] [Related]

  • 14. Lipids, lipoproteins and apolipoproteins abnormalities in patients undergoing dialysis.
    Yang X, Wang H, Zhu Z, Deng A.
    J Tongji Med Univ; 1997 Jan; 17(2):126-8. PubMed ID: 9639806
    [Abstract] [Full Text] [Related]

  • 15. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency.
    Lee DM, Knight-Gibson C, Samuelsson O, Attman PO, Wang CS, Alaupovic P.
    Kidney Int; 2002 Jan; 61(1):209-18. PubMed ID: 11786103
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures.
    Milionis HJ, Elisaf MS, Karabina SA, Bairaktari E, Tselepis AD, Siamopoulos KC.
    Kidney Int; 1999 Dec; 56(6):2276-85. PubMed ID: 10594806
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis.
    Saltissi D, Morgan C, Rigby RJ, Westhuyzen J.
    Am J Kidney Dis; 2002 Feb; 39(2):283-90. PubMed ID: 11840368
    [Abstract] [Full Text] [Related]

  • 19. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients.
    Tomura S, Nakamura Y, Doi M, Ando R, Ida T, Chida Y, Ootsuka S, Shinoda T, Yanagi H, Tsuchiya S, Marumo F.
    Am J Kidney Dis; 1996 Jun; 27(6):848-54. PubMed ID: 8651250
    [Abstract] [Full Text] [Related]

  • 20. Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.
    Navarro JF, Mora C, Muros M, García-Idoate G.
    Nephron Clin Pract; 2003 Jun; 95(4):c128-35. PubMed ID: 14694274
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.